Afya (NASDAQ:AFYA) CEO Virgilio Deloy Capobian Gibbon Sells 2,320 Shares

Afya Limited (NASDAQ:AFYA) CEO Virgilio Deloy Capobian Gibbon sold 2,320 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $14.92, for a total value of $34,614.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Virgilio Deloy Capobian Gibbon also recently made the following trade(s):

• On Wednesday, April 1st, Virgilio Deloy Capobian Gibbon sold 19,500 shares of Afya stock. The stock was sold at an average price of $14.98, for a total value of $292,110.00.
• On Thursday, March 26th, Virgilio Deloy Capobian Gibbon sold 800 shares of Afya stock. The stock was sold at an average price of $15.21, for a total value of $12,168.00.
• On Wednesday, March 25th, Virgilio Deloy Capobian Gibbon sold 3,900 shares of Afya stock. The shares were sold at an average price of $15.18, for a total transaction of $59,202.00.

Afya Stock Performance

Shares of Afya stock traded down $0.03 during midday trading on Thursday, hitting $14.94. The company had a trading volume of 81,377 shares, compared to its average volume of 116,128. The company has a fifty day simple moving average of $14.45 and a 200 day simple moving average of $14.73. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 0.66 and a beta of 0.48. The company has a quick ratio of 0.98, a current ratio of 2.20 and a debt-to-equity ratio of 0.21. Afya Limited has a 12-month low of $13.00 and a 12-month high of $19.90.

Afya (NASDAQ:AFYA) last released its earnings results on Wednesday, March 11th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.05. Afya had a net margin of 20.31% and a return on equity of 18.77%. The company had revenue of $147.08 million for the quarter, compared to the consensus estimate of $174.74 million. As a group, analysts predict that Afya Limited will post 1.52 earnings per share for the current fiscal year.

Afya Dividend Announcement

The business also recently disclosed an annual dividend, which will be paid on Monday, April 6th. Stockholders of record on Wednesday, March 25th will be issued a dividend of $0.656 per share. The ex-dividend date of this dividend is Wednesday, March 25th. This represents a dividend yield of 433.0%. Afya’s payout ratio is 44.52%.

Institutional Investors Weigh In On Afya

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Van ECK Associates Corp raised its stake in shares of Afya by 15.7% during the 3rd quarter. Van ECK Associates Corp now owns 10,170 shares of the company’s stock valued at $159,000 after buying an additional 1,377 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Afya during the fourth quarter worth about $43,000. Arrowstreet Capital Limited Partnership grew its holdings in Afya by 5.6% during the second quarter. Arrowstreet Capital Limited Partnership now owns 68,169 shares of the company’s stock worth $1,217,000 after acquiring an additional 3,626 shares during the period. Dodge & Cox raised its position in Afya by 12.8% during the second quarter. Dodge & Cox now owns 35,262 shares of the company’s stock valued at $630,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Militia Capital Partners LP purchased a new position in Afya during the second quarter valued at approximately $71,000. 88.02% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on AFYA. Sanford C. Bernstein raised Afya to a “market perform” rating in a research report on Friday, January 16th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $22.00 price objective (down from $24.50) on shares of Afya in a report on Wednesday, January 7th. Wall Street Zen upgraded Afya from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. UBS Group reaffirmed a “neutral” rating and set a $16.00 target price (down from $18.00) on shares of Afya in a report on Friday, January 16th. Finally, Bank of America downgraded shares of Afya from a “buy” rating to a “neutral” rating and cut their price target for the stock from $22.00 to $17.00 in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.30.

About Afya

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.